Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers
PLOS One · 2025
DOI: 10.1371/journal.pone.0322744 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Teresa H Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA. Hauptthemen laut MEDLINE: Receptors, Androgen, Ovarian Neoplasms, Androgen Receptor Antagonists, Androgen Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: BLRD VA, NCI NIH HHS, Department of Veteran Affairs.
Abstract (Originalsprache)
Introduction
Androgen promotes tumorigenesis in some cancers; however, androgen receptor (AR) is not commonly examined in ovarian cancers (OCs). In this study, we evaluated AR expression among different types of OCs and compared the results to estrogen and progesterone receptors (ER & PR). Materials and methods AR, ER, and PR expressions were assessed in 62 cases which were categorized into: low-grade serous carcinoma (LGSCA), high-grade serous carcinoma (HGSCA), clear cell carcinoma (CCCA), ovarian endometrioid carcinoma (OECA), and granulosa cell tumor (GCT). The hormone receptors were compared and evaluated in relation to p53 and body mass index (BMI) using Fisher’s Exact test.
Results
In a majority of cases, expression of AR was concordant with ER and/or PR. Positivity for all three receptors was observed in 100% of OECAs. AR expression was seen in 92% of HGSCAs as opposed to 88% and 44% for ER and PR. LGSCAs had expressed AR and ER (100%), and PR (70%). In GCTs, positivity rates were 92%, 62%, and 92% for AR, ER, and PR. In rare cases of HGSCA and CCCA, AR was positive despite negative ER and PR.
Conclusion
AR is expressed in a high percentage of OCs, even more frequently than ER and PR in certain high-grade histological types. Overall, our findings are similar to the results of recent studies of AR expression in endometrial cancers. These findings support an important possible role for AR in OCs as a potential marker to serve as a therapeutic target in these malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, CA.
- Johnson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA.
- Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA.
- VA Greater Los Angeles Healthcare System, Los Angeles, CA.
ORCID-Profile: Neda A Moatamed
Förderung
- BLRD VA
- NCI NIH HHS
- Department of Veteran Affairs
Zitieren
APA
Kim, T. H., Memarzadeh, S., Vahdatshariatpanahi, S., Ostrzega, N., Kang, Y., & Moatamed, N. A. (2025). Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers. PLOS One. https://doi.org/10.1371/journal.pone.0322744
Vancouver
Kim TH, Memarzadeh S, Vahdatshariatpanahi S, Ostrzega N, Kang Y, Moatamed NA. Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers. PLOS One. 2025. doi:10.1371/journal.pone.0322744
BibTeX
@article{Kim2025,
author = {Kim, Teresa H and Memarzadeh, Sanaz and Vahdatshariatpanahi, Saba and Ostrzega, Nora and Kang, Yuna and Moatamed, Neda A},
title = {Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322744}
}
EUVIMED